期刊文献+

SHEL模式对门诊药房高危药品管理的有效性分析 被引量:5

Analysis of the effectiveness of SHEL model in outpatient pharmacy management of high-risk drugs
下载PDF
导出
摘要 目的探讨SHEL(S-soft:软件部分,H-hard:硬件部分,E-envinnment:临床环境,L-litigant:当事人及他人)模式对门诊药房高危药品管理的有效性,为提高门诊药房高危药品管理提供参考依据。方法实施常规模式管理的门诊药房高危药品作为对照组,实施SHEL模式管理的门诊药房高危药品作为观察组,比较门诊高危药品发药差错事件发生率、发生原因和满意度。结果观察组差错发生率为0.03%,对照组0.18%,观察组因个人素质发生差错占16.67%,低于对照组的62.16%,观察组实施后满意率为98.33%,高于实施前的92.50%,以上比较差异有统计学意义(P<0.05)。结论 SHEL模式降低了门诊药房高危药品发放差错率,人员素质是发药差错的主要原因。 Objective To evaluate the effectiveness of SHEL(Soft Hard Environment Litigant) model on the outpatient pharmacy management of high-risk drugs to provide reference for improving outpatient pharmacy management of high-risk drugs. Methods High-risk drugs in outpatient pharmacy implemented conventional management model as control group, high-risk drugs in outpatient pharmacy implemented SHEL management model as observation group, diagnosis of high-risk drug dispensing errors occurred, the causes and the degree of satisfaction were compared. Results The observation group error rate was 0.03%, 0.18%of the control group, for personal quality errors in observation group accounted for 16.67%, lower than that of the control group 62.16%, satisfaction rate of observation group after implementation(98.33%) was higher than before implementation(92.50%), with statistical significance difference(P〈0.05). Conclusion SHEL pattern reduces error rate of high-risk drugs in outpatient pharmacy, the quality of personnel is the main reason for dispensing errors.
出处 《中国实用医药》 2014年第22期257-259,共3页 China Practical Medicine
关键词 门诊药房 高危药品 安全管理 SHEL模式 Outpatient pharmacy High-risk drug Safety management SHEL model
  • 相关文献

参考文献10

二级参考文献31

  • 1林志强.医疗机构药品不良反应监测模式探讨[J].中国药物警戒,2006,3(2):119-121. 被引量:24
  • 2Shlom E A. May S IL Managing high-risk medications:imple-menting medication raanagement standard 7.10 [J] . Hosp Pharm, 2006,41 (5) :470-476.
  • 3Institute for Safe Medication Practices. ISMP' s list of high- alert medications[EB/OL]. (2012-05) [2013-02-20]. ht- tp : //www.ismp.org/Tools/highalertmedicati ons.pdf.
  • 4Belknap S. High-alert medications and patient safety[J]. Int J Qual Health Care,2001,13(4) :339.
  • 5Cohen MR, Kilo CM. High-alert medications: safeguard- ing against errors. Medication error[M]. 2nd edition. Washington, DC: American Hospital Association, 2007: 317-413.
  • 6Graham S, Clopp MP, Kostek NE, et al. Implementation of a high-alert medication program[J]. Perm J, 2008, 12 (2):15.
  • 7Klepstad P, Kaasa S, Borchgrevink PC.Starting step llI opi- oids for moderate to severe pain in cancer patients doseti- tration: a systematic review[J]. Palliat Med,2011,25(5) : 424.
  • 8Wiffen PJ, McQuay HJ. Oral morphine for cancer pain[J]. Cochrane Database Syst Rev, 2007 (4) : CD003868.
  • 9Ljuca D, Husic S.Treatment of severe cancer pain by trans- dermal fentany[J]. Bosh J Basic Med Sci, 201 O, 10 ( 2 ) : 158.
  • 10Jensen MP, Chang HY, Lai YH, et al. Pain in long-term breast cancer survivors: frequency, severity, and impact [J]. Pain Med,2010, 11(7) : 1 099.

共引文献76

同被引文献28

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部